ProCE Banner Activity

CPX-351 and HMA + Venetoclax as Frontline Therapy in AML: A Retrospective Comparative Analysis

Slideset Download
Conference Coverage
Retrospective analysis of newly diagnosed patients with AML suggests similar response rates and, in the overall patient population, longer overall survival with frontline CPX-351 compared with a hypomethylating agent plus venetoclax.

Released: December 14, 2021

Expiration: December 13, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation